This category covers biotechnology and pharmaceutical companies developing therapies targeting ferroptosis — an iron-dependent form of regulated cell death characterized by lipid peroxidation accumulation — for the treatment of Parkinson's disease (PD). Ferroptosis is increasingly recognized as a key mechanism contributing to dopaminergic neuron loss in PD, with evidence pointing to impaired glutathione peroxidase 4 (GPX4) function, iron dyshomeostasis in the substantia nigra, and lipid peroxidation accumulation.
Unlike apoptosis or necrosis, ferroptosis is distinctively characterized by:
- Iron-dependent accumulation of lipid peroxides
- Loss of GPX4 activity leading to membrane lipid damage
- Sensitivity to iron chelation and lipid antioxidant treatment
- Distinct morphological features (smaller mitochondria, dense membrane)
The substantia nigra pars compacta is particularly vulnerable to ferroptosis due to:
- High iron accumulation in PD brains
- Elevated ACSL4 expression making dopaminergic neurons highly sensitive
- Dopamine oxidation generating reactive oxygen species
- Limited antioxidant capacity compared to other neuronal populations
Companies in this space pursue several mechanisms targeting different nodes of the ferroptosis pathway, including iron chelation, GPX4 activation, lipid peroxidation scavenging, System Xc- modulation, and FSP1/CoQ10 augmentation.
Reducing labile iron availability that drives Fenton reactions and lipid peroxide formation. Deferiprone and similar BBB-penetrant chelators have shown clinical data in PD.
Restoring or enhancing GPX4 function to reduce lipid peroxides. Includes direct GPX4 modulators, selenium supplementation, and upregulation strategies.
Scavenging lipid peroxyl radicals before they damage membranes. Ferrostatin-1 analogs and lipophilic antioxidants.
The cystine/glutamate antiporter (SLC7A11/SLC3A2) imports cystine for GSH synthesis. Modulators can enhance this pathway to restore cellular antioxidant capacity.
FSP1-mediated CoQ10 reduction provides alternative lipid peroxidation defense independent of GPX4.
- Focus: Iron chelation therapy
- Lead Candidate: Deferiprone (Ferriprox/Kelfer)
- Indication: Parkinson's disease
- Stage: Phase II completed, Phase III planning
- Mechanism: Oral iron chelator that crosses the blood-brain barrier and reduces brain iron stores implicated in ferroptosis
- Clinical Data: FAIRPARK-II trial demonstrated significant brain iron reduction in substantia nigra and putamen, with signal of reduced disease progression on MDS-UPDRS[moreau2022]
- Related Page: Apopharma Inc.
- Focus: CoQ10 supplementation for mitochondrial/ferroptosis protection
- Lead Candidates: Ubiquinol, mitochondrial-targeted CoQ10
- Indication: Parkinson's disease
- Stage: Phase II/III
- Mechanism: Supports FSP1-mediated ferroptosis defense through CoQ10 redox cycling
- Notes: CoQ10 provides GPX4-independent lipid peroxidation protection via the FSP1 pathway
- Focus: GPX4-targeted small molecules
- Lead Candidates: FRX-101, FRX-201 (research compounds)
- Indication: Parkinson's disease / ALS
- Stage: Discovery/Preclinical
- Mechanism: Direct GPX4 activity modulators designed to prevent ferroptotic cell death in dopaminergic neurons
- Notes: Academic-industry collaboration focused on ferroptosis modulation; working on BBB-penetrant analogs of known GPX4 modulators
- Focus: Mitochondria-targeted antioxidants
- Lead Candidate: MT-101
- Indication: Parkinson's disease / Neurodegeneration
- Stage: Preclinical
- Mechanism: CoQ10 redox augmentation targeting mitochondrial ferroptosis defense through FSP1 pathway
- Notes: Works through FSP1/CoQ10 pathway which provides GPX4-independent lipid peroxidation defense
- Related Page: MitoThera
- Focus: Nanocrystalline cleans for neurodegenerative diseases
- Lead Candidate: CNM-Au8
- Indication: Parkinson's disease (exploratory) / ALS
- Stage: Phase 2
- Mechanism: Redox-active gold nanocrystals that support antioxidant pathways including those relevant to ferroptosis
- Notes: Demonstrated improvement in neuronal survival in preclinical ferroptosis models
- Related Page: Clene Nanomedicine
- Focus: Clinical translation of iron chelation in PD
- Key Researchers: Prof. David Devos, Dr. Caroline Moreau
- Mechanism Areas: Brain iron metabolism, deferiprone clinical trials
- Notes: Leading academic center for ferroptosis-targeted therapy in PD; FAIRPARK program represents most advanced clinical data
- Focus: Basic research on ferroptosis mechanisms in dopaminergic neurons
- Key Researchers: Various
- Mechanism Areas: GPX4 biology, ACSL4 vulnerability, System Xc- dysfunction
- Notes: Academic research consortium providing mechanistic foundations for ferroptosis-targeted drug development
| Company |
Drug |
Mechanism |
Indication |
Stage |
| Apopharma |
Deferiprone |
Iron chelation |
PD |
Phase II completed |
| Various |
CoQ10 |
FSP1/CoQ10 axis |
PD |
Phase II/III |
| Ferro Rx |
FRX-101 |
GPX4 modulation |
PD/ALS |
Discovery |
| MitoThera |
MT-101 |
CoQ10 augmentation |
Neurodegeneration |
Preclinical |
| Clene |
CNM-Au8 |
Nanocrystal redox |
PD/ALS |
Phase 2 |